Grzechocinska Barbara, Gadomska Halina, Zygula Aleksandra, Wielgos Miroslaw
Neuro Endocrinol Lett. 2014;35(3):175-8.
Uterine fibroids are the most common benign tumors in women of reproductive age. Evidence suggest that ovarian steroid hormones, in particular, progesterone play a major role in promoting leiomyoma development and growth. For the last years there was an extensive research on selective progesterone receptor modulators and their use in therapy. Ulipristal acetate (UPA) is one of these modulators. The aim of this paper is to evaluate efficacy and safety of oral ulipristal acetate for the treatment in women with symptomatic uterine fibroids.
The study group comprised five patients with uterine fibroids. All patients received 5 mg of ulipristal acetate per day for three months.
The total volume of fibroids decreased by 33-68%. In all patients during the administration of UPA significant reduction of menstrual bleeding was observed. Increase of endometrial thickness without clinical significance was observed in two patients. No significant side-effects were observed during the treatment period.
子宫肌瘤是育龄期女性最常见的良性肿瘤。有证据表明，卵巢甾体激素，尤其是孕酮，在促进平滑肌瘤的发生和生长中起主要作用。近年来，对选择性孕酮受体调节剂及其在治疗中的应用进行了广泛研究。醋酸乌利司他（UPA）就是其中一种调节剂。本文旨在评估口服醋酸乌利司他治疗有症状子宫肌瘤女性的疗效和安全性。
研究组包括5例子宫肌瘤患者。所有患者每天服用5mg醋酸乌利司他，持续3个月。
肌瘤总体积减少了33%至68%。在所有服用UPA的患者中，均观察到月经出血量显著减少。2例患者出现子宫内膜厚度增加，但无临床意义。治疗期间未观察到明显副作用。
1）肌瘤体积减少了33%至68%。2）服用UPA可有效控制过多出血。3）UPA治疗可能会改变手术范围。4）UPA是一种耐受性良好的药物。
